Evaluation of glycated albumin and microalbuminuria as early risk markers of nephropathy in type 2 diabetes mellitus

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 7, 2013, Pages 1280-1283

  Babu Kondaveeti, Suresh ^a   Kumaraswamy, D ^b   Mishra, Shishir ^b   Aravind Kumar, R ^a   Anand Shaker, I ^a  

^a Melmaruvathur Adi Parasakthi Institute of Medical Science and Research   (India)

^b SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Diabetic nephropathy; Glycated albumin; Microalbuminuria

Indexed keywords

ANTIDIABETIC AGENT; CREATININE; GLYCOSYLATED ALBUMIN;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR;

EID: 84879979101     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/5145.3117     Document Type: Article

References (18)

1. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26 (Suppl 1):5-20.
2. 1999 United States Renal Data System Annual Report: National Technical Information Service. US Department of Health and Human Services, Springfield, VA.
3. Satchell S, Tooke JF. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008;51:714-25.
4. Powers AC. Diabetes Mellitus. In: Jameson JL. (editor) Harrison's Endocrinology. 1st ed. New York: McGraw-Hill; 2006;303-04.
5. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1358-73.
6. Vergouwe Y, Soedamah-Muthu SS, Zgibor J, Chaturvedi N, Forsblom C, Snell-Bergeon JK, et al. Progression to microalbuminuria in type 1diabetes: development and validation of a prediction rule. Diabetologia. 2010;53:254-62.
7. Kouzuma T. Study of glycated amino acid elimination for an improved enzymatic glycated albumin measurement method. Clin Chim Acta. 2004; 346: 135-43.
8. Jacobs NJ, Van Denmark PJ, Enzymatic determinationof serum triglyceride. Biochem. Biophys.1960; 88:250-55.
9. American Diabetes Association. Testing in Asymptomatic Patients. Diabetes Care. 2011;34(Suppl 1):13-14.
10. Ghai R, Verma ND, Goel A, Bhatnagar MK, Kapoor P, Vashishta A. Microalbuminuria in non insulin dependent diabetes and essential hypertension: A marker of severe disease. J Assoc Physicians India. 1994;42:771-74
11. Chujo K, Shima K, Tada H, Oohasi T, Minakuchi J, Kawashima S. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHB vs glycated albumin (GA). J Med Invest. 2006;53:223-28.
12. Chalew S, McCarter R, Thomas J, Thomson J, Hempe J. A comparison of the glycosylation gap and haemoglobin glycation index in patients with diabetes. Journal of Diabetes and Its Complications. 2005; 19:218-22.
13. Hudson PR, Child DF, Jones H, Williams CP. Differences in rates of glycation (glycation index) may significantly affect individual HbA1c results in type 1 diabetes. Annals of Clinical Biochemistry. 1999; 36:451-59.
14. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Intern. 2008; 73:1062-68.
15. (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocrinology Journal. 2007;1507: 6-103.
16. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:1413-18.
17. Jungmann E, Helling T, Jungmann G, Mertens C, Snelting U. Inetensified conventional insulin therapy in patients with type 2 diabetes mellitus: Positive long-term effects of insulin lispro on metabolic control and microalbuminuria. Fortschr Med Orig. 2001;118:141-46.
18. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al. Randomized controlled trial of dual blockade of renin Angiotensin system in patients with hypertension, microalbuminuria and insulin dependent diabetes mellitus: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ.2000;321:1440-44.